Amylyx Pharmaceuticals Raises $135M in Series C Financing

22 Jul, 2021

Amylyx Pharmaceuticals Raises $135M in Series C Financing
Photo by Marten Bjork on Unsplash

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Biotechnology Medical Neuroscience North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: